Airdoc 鹰瞳科技
Retinal-image AI for chronic-disease screening from a single eye scan
Overview
Airdoc (鹰瞳科技) is a Hong Kong-listed medical-AI company specialising in retinal-image analysis for early screening and predictive assessment of chronic diseases. Its AI fundus systems detect dozens of eye conditions and chronic-disease risk indicators such as diabetes and hypertension from a retinal scan, and it markets a multi-condition assessment report. The company holds NMPA and EU CE (MDR) certifications and reports tens of millions of users served.
ASEAN Perspective
Airdoc 鹰瞳科技 in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Airdoc is a serious, regulated medical-AI company, not a consumer app: its retinal-imaging screening has NMPA and EU CE clearances and a large deployed user base, which is rare in this space. The single-scan, multi-condition screening approach is genuinely differentiated and clinically oriented.
It is sold through healthcare institutions and partners with no public API or self-serve access, and clinical claims should be read in the context of regional regulatory approval. CE certification helps international credibility, but ASEAN availability depends on local medical-device clearance and partner channels.
About this listing
This entry was compiled from publicly available data including Airdoc 鹰瞳科技's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Airdoc 鹰瞳科技 unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Airdoc 鹰瞳科技 directly →
Spotted something out of date? Suggest an update →
More in Other
